Nanocarriers transport across the gastrointestinal barriers: The contribution to oral bioavailability via blood circulation and lymphatic pathway.

Application Bioavailability Gastrointestinal barrier Nanotechnology Oral drug delivery Transport mechanism

Journal

Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523

Informations de publication

Date de publication:
12 2023
Historique:
received: 20 08 2023
revised: 27 09 2023
accepted: 27 10 2023
medline: 11 12 2023
pubmed: 2 11 2023
entrez: 1 11 2023
Statut: ppublish

Résumé

Oral administration is the preferred route of drug delivery in clinical practice due to its noninvasiveness, safety, convenience, and high patient compliance. The gastrointestinal tract (GIT) plays a crucial role in facilitating the targeted delivery of oral drugs. However, the GIT presents multiple barriers that impede drug absorption, including the gastric barrier in the stomach and the mucus and epithelial barriers in the intestine. In recent decades, nanotechnology has emerged as a promising approach for overcoming these challenges by utilizing nanocarrier-based drug delivery systems such as liposomes, micelles, polymeric nanoparticles, solid lipid nanoparticles, and inorganic nanoparticles. Encapsulating drugs within nanocarriers not only protects them from degradation but also enhances their transport and absorption across the GIT, ultimately improving oral bioavailability. The aim of this review is to elucidate the mechanisms underlying nanocarrier-mediated transportation across the GIT into systemic circulation via both the blood circulation and lymphatic pathway.

Identifiants

pubmed: 37913890
pii: S0169-409X(23)00445-3
doi: 10.1016/j.addr.2023.115130
pii:
doi:

Substances chimiques

Drug Carriers 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115130

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ding Wang (D)

College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, PR China.

Qi Jiang (Q)

College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, PR China.

Zhefan Dong (Z)

College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, PR China.

Tingting Meng (T)

College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, PR China.

Fuqiang Hu (F)

College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, PR China.

Jianwei Wang (J)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 310009, PR China.

Hong Yuan (H)

College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, PR China; China Jinhua Institute of Zhejiang University, Jinhua 321299, PR China. Electronic address: yuanhong70@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH